Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of oral HX9428 versus intravitreal aflibercept in neovascular age-related macular degeneration
CTR20262884Phase 2Active
- Sponsor
- Haixi New Pharma
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HX9428 in exudative macular degeneration (2 arms), sponsored by Haixi New Pharma. Started Jul 2026; status: active.
02
Drugs
HX9428
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20262884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262884.